C4 Therapeutics, Inc.

CCCC

US12529R1077

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:04:28 16/07/2024 pm IST			5-day change	1st Jan Change
7.09 ^USD	+9.24%		+39.30%	+23.27%

15/07	Transcript : C4 Therapeutics, Inc. Presents at UBS Virtual Targeted Protein Degradation Day, Jul-15-2024 12:00 PM
01/07	C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell Small Cap Comp Value Index	CI

C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell 2000 Value Index

July 01, 2024

Latest news about C4 Therapeutics, Inc.

Transcript : C4 Therapeutics, Inc. Presents at UBS Virtual Targeted Protein Degradation Day, Jul-15-2024 12:00 PM	15/07
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell Small Cap Comp Value Index	01/07	CI
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell Small Cap Completeness Index	01/07	CI
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell 3000 Value Index	01/07	CI
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell 2000 Index	01/07	CI
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell 3000E Index	01/07	CI
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell 2500 Value Index	01/07	CI
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell 2000 Value Index	01/07	CI
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell 2000 Dynamic Index	01/07	CI
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell 2500 Index	01/07	CI
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell 3000 Index	01/07	CI
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to Russell 3000E Value Index	01/07	CI
C4 Therapeutics Appoints Ron Cooper Board Chairman	10/06	MT
C4 Therapeutics, Inc. Announces Board and Committee Changes	10/06	CI
Stifel Adjusts Price Target on C4 Therapeutics to $14 From $13, Maintains Buy Rating	09/05	MT
C4 Therapeutics Shares Decline as Q1 Revenue Misses Estimates	09/05	MT
C4 Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
C4 Therapeutics, Inc. Presents New Preclinical Data for CFT1946 Highlighting Superior Activity as a Single Agent to Clinically Approved BRAF Inhibitor Standard of Care Combinations at the American Association for Cancer Research Annual Meeting 2024	08/04	CI
C4 Therapeutics, Inc.(NasdaqGS:CCCC) added to S&P Biotechnology Select Industry Index	18/03	CI
C4 Therapeutics Collaborating With Germany's Merck KGaA to Advance Research on Targeted Therapies for Cancer	04/03	MT
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA Against Critical Oncogenic Proteins	04/03	CI
Morgan Stanley Adjusts Price Target on C4 Therapeutics to $8 From $1, Maintains Equal-Weight Rating	26/02	MT
C4 Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/02	CI
North American Morning Briefing : Stock Futures -2-	21/02	DJ
North American Morning Briefing : Microsoft Kicks -2-	30/01	DJ

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on advancing targeted protein degradation science to create a new generation of small-molecule medicines that transform patientsâ lives. By leveraging its proprietary Target ORiented ProtEin Degrader Optimizer (TORPEDO) platform, to design and optimize small molecule protein degraders that are active against their desired targets by harnessing the bodyâs natural process for destroying unwanted proteins. Its TORPEDO platform has the capability to design two types of protein degraders and both degrader approaches are reflected in its clinical pipeline. Its product candidate, CFT7455, is an orally bioavailable MonoDAC degrader of protein targets called IKZF1 and IKZF3, which are in clinical development for multiple myeloma and non-Hodgkin lymphoma. Its CFT1946 is an orally bioavailable BiDAC degrader designed to be potent and selective against BRAF V600X mutant proteins. It is also developing CFT8919.

Sector

Biotechnology & Medical Research

Calendar

07/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for C4 Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

6.49 USD

Average target price

17.38 USD

Spread / Average Target

+167.72%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
C4 THERAPEUTICS, INC.	+23.27%	447M
MODERNA, INC.	+24.57%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.12%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+33.87%	32.4B
ICON PUBLIC LIMITED COMPANY	+20.58%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+49.17%	14.52B
MEDPACE HOLDINGS, INC.	+47.18%	13.74B
BIO-TECHNE CORPORATION	+2.14%	12.17B

Other Biotechnology & Medical Research